Home › Science › Discovery of a covalent FGFR2-selectiv
SCIENCE

Nature Communications Details Covalent FGFR2 Inhibitor

Nature Communications published research detailing a covalent FGFR2-selective inhibitor overcoming clinically-acquired resistance mutations.

By Xentir Media Newsroom · Editorial standards by Jomon · August 04, 2026 · Updated August 05, 2026 · 1 min read
WHAT YOU NEED TO KNOW
  • Source: Nature Communications
  • DOI: 10.1038/s41467-026-76339-0
  • Publication date: 2026-08-03T00:00:00Z

Nature Communications published a peer-reviewed study detailing the discovery of a covalent FGFR2-selective inhibitor designed to overcome clinically-acquired resistance mutations.

The source published the research on August 3, 2026, under the digital object identifier 10.1038/s41467-026-76339-0.

SOURCES
Nature Communications Details Covalent FGFR2 Inhibitor overcoming clinically-acquired resistance mutations — Nature Communications
Peer reviewed · Nature Communications · DOI 10.1038/s41467-026-76339-0
Xentir Media
Xentir Media NewsroomSource-backed AI and technology coverage, drafted by Xentir's automated editorial system under fixed human-set rules. See our editorial policy and AI usage policy.
J
Jomon · Founder & EditorFounder and editor of Xentir Media. Sets the editorial rules the newsroom system runs under, and is accountable for its corrections. About Jomon · [email protected]
The Xentir Brief
The developments worth knowing — one useful email.
Get the Brief →
IN THE AI INDEX

The models leading the Xentir AI Index right now:

GPT-6 Astra · #1 overallClaude Fable 5.1 · #2 overallClaude Fable 5 · #3 overallCompare: Claude Fable 5 vs Claude Opus 5 →See the full AI Model Rankings →
RELATED ON XENTIRNature Communications Publishes Research on Population GeometryNature Communications Publishes Climate and Biodiversity StudyNature Communications Publishes Microcomb Quantum Network StudyWave morphing published in Nature Communications